During their meeting on 6 December 2016, the Leem Board of Directors (Les Entreprises du Médicament) [The pharmaceutical Industry] appointed a new director, Stéphane Thiroloix, General Manager of the Laboratoires Mayoly Spindler, a “Medium-sized French Laboratory”.
Stéphane Thiroloix is a graduate of the HEC (École des Hautes Études Commerciales [Paris Business School]).
He began his career in 1987 at Roussel Uclaf (now Sanofi), where, for eleven years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.
In 1998, he joined SmithKline Beecham (now GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President for Europe in Business Development and Marketing Alliances.
From 2002 to 2007, Stéphane Thiroloix was Vice-President of French Operations and then became Vice-President for Europe and General Manager for France at Bristol-Myers Squibb.
In 2007, he joined the Ispen company’s executive committee as Executive Vice-President of Corporate Development and held this position until 2011, the year he became President of Smith & Nephew’s Advanced Surgical Devices (ASD) Division for Europe, Canada, Japan and Australia.
In 2014, Stéphane Thiroloix became General Manager of Laboratoires Mayoly Spindler.
Mayoly Bela officially opened in November 17th 2016.
Belarus is a major market in CIS region where Mayoly Spindler commercializes its products since 15 years.
Business center “Victoria Olimp”
Bulvard Pabediteliy, 103
Office # 1314
There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.
BROOKLYN, N.Y., 17 NOV. 2016 (GLOBE NEWSWIRE) ‐‐ AZURRX BIOPHARMA INC. (NASDAQ:AZRX)
(“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).
The open-label, dose escalation Phase II study is being conducted in two sites in Australia
The Royal Adelaide Hospital and Linear Clinical Research in Perth as well as two sites in New Zealand, P3 Research in Wellington and CCST in Christchurch. The study is projected to enroll approximately 12 patients with EPI caused by chronic pancreatitis over the next several months. Dr. Quoc Nam Ngyuen, Associate Professor in the Department of Gastroenterology at the Royal Adelaide Hospital is the principal investigator for the study.
The primary objective of this Phase II study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Initial study results from the MS1819-SD Phase II study are expected in the first half of 2017.
|In September 2016, Mayoly Spindler launched a new gastroenterology medical device BabySpasmyl®, recommended for the treatment of infant colic, aerophagia, bloating and gastrointestinal disorders in adults, children and infants from one month old.
BabySpasmyl® is a simethicone-based medical device (with recognised physical and mechanical actions against wind).
The BabySpasmyl® dosage:
Infants: 20 drops (around 1 ml) 1-2 times a day
Children: (20 drops, 1-3 times a day)
Adultes : 20-40 gouttes 2-4 fois par jour
BabySpasmyl® is a simethicone-based medical device with physical and mechanical actions, which helps in relieving infant colic, aerophagia, bloating and gastrointestinal disorders in adults, children and infants. It is manufactured by NTC. Read the package leaflet carefully before use. In case of doubt, ask your doctor or pharmacist. This medical device is a regulated healthcare device that, in accordance with this regulation, has the (CE 0426) CE marking, issued by ITALCERT. November 2016.
Paris, Wednesday, October 5, 2016
MAYOLY SPINDLER acquires the Swedish laboratory Kibion and becomes the leading company in the market of detecting and control of Helicobacter pylori infections.
|Mayoly Spindler, the independent French benchmark laboratory in gastroenterology and dermocosmetics, is continuing its international development with the acquisition of the young Swedish laboratory Kibion. Mayoly Spindler has there by become the leading company in the market of urea breath tests used to diagnose the presence of Helicobacter pylori and control its eradication.
>Press release in english